Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: Hank who wrote (2636)	10/16/2000 7:05:08 PM
From: DanZ	Read Replies (2) \| Respond to of 5582

Your BS takes the cake, Hank. The marketing data listed below was reported in the June 99 issue of Discount Merchandiser. 1. Private Label: $730.7 million 2. Tylenol: $257.3 million 3. Robitussen: $165.2 million 4. Benadryl: $165.2 million 5. Sudafed: $161.6 million 6. NyQuil: $136.5 million 7. Alka Seltzer: $119.6 million 8. Dimetapp: $92.4 million 9. Theraflu: $57.4 million 10. Formula 44: $57.2 million Total Cough and Cold category: $2.391 billion So are we to believe that manufacturers spend billions of dollars each year to generate $2.4 billion in sales? Gee, I wonder how J&J makes any money on Tylenol, or how any of the companies make money on their cough and cold products. According to you, they consistently spend more money on advertising than they generate in sales. Oh, you mean there's a difference between prescription drugs and OTC medicine? What's your point then? BTW, didn't you say that a study on Zicam would never be published? Oops, looks like you were wrong--Again. BTW #2, I never said that every doctor that reads the article will recommend Zicam to their patients. So what's your point? Yeah I know, you don't have one.